

S4 Table. Use of novel agents for MM patients according to age and presence, severity, and type of disabilities

	Patients < 65 yr		Patients ≥ 65 yr	
	Bortezomib	Thalidomide	Bortezomib	Thalidomide
All patients	649 (50.7)	610 (47.6)	1,497 (53.3)	517 (18.4)
Patients without disability	520 (50.7)	489 (47.7)	1,214 (53.8)	426 (18.9)
Patients with disability	129 (50.4)	121 (47.3)	283 (51.2)	91 (16.5)
Severity of disability				
Severe (grade 1, 2, 3)	48 (44.9)	45 (42.1)	77 (51.0)	23 (15.2)
Mild (grade 4, 5, 6)	81 (54.4)	76 (51.0)	206 (51.2)	68 (16.9)
Type of disability				
Physical	83 (50.6)	81 (49.4)	187 (54.7)	60 (17.5)
Communication	25 (67.6)	21 (56.8)	81 (47.4)	26 (15.2)
Intellectual or psychological	4 (22.2)	8 (44.4)	0 (0.0)	0 (0.0)
Major internal organ	17 (45.9)	11 (29.7)	15 (42.9)	5 (14.3)

Values are presented as number (%). MM, multiple myeloma.